GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CardioGenics Holdings Inc (OTCPK:CGNH) » Definitions » Net Income

CardioGenics Holdings (CardioGenics Holdings) Net Income : $-0.98 Mil (TTM As of Jan. 2016)


View and export this data going back to 2004. Start your Free Trial

What is CardioGenics Holdings Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. CardioGenics Holdings's Net Income for the three months ended in Jan. 2016 was $-0.13 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jan. 2016 was $-0.98 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. CardioGenics Holdings's Earnings per Share (Diluted) for the three months ended in Jan. 2016 was $-0.00.


CardioGenics Holdings Net Income Historical Data

The historical data trend for CardioGenics Holdings's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardioGenics Holdings Net Income Chart

CardioGenics Holdings Annual Data
Trend Jul06 Jul07 Jul08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.73 -1.31 -2.92 -2.68 -1.92

CardioGenics Holdings Quarterly Data
Apr11 Jul11 Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Jul15 Oct15 Jan16
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.06 0.12 -0.61 -0.37 -0.13

CardioGenics Holdings Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

CardioGenics Holdings's Net Income for the fiscal year that ended in Oct. 2015 is calculated as

Net Income(A: Oct. 2015 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.916+0+0+0
=-1.92

CardioGenics Holdings's Net Income for the quarter that ended in Jan. 2016 is calculated as

Net Income(Q: Jan. 2016 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.125+0+0+0
=-0.13

Net Income for the trailing twelve months (TTM) ended in Jan. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CardioGenics Holdings  (OTCPK:CGNH) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

CardioGenics Holdings's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jan. 2016 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


CardioGenics Holdings Net Income Related Terms

Thank you for viewing the detailed overview of CardioGenics Holdings's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


CardioGenics Holdings (CardioGenics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
6295 Northam Drive, Unit 8, Mississauga, ON, CAN, L4V 1W8
CardioGenics Holdings Inc is a biotechnology company. It is engaged in the development and commercialization of diagnostic test products for the In-Vitro Diagnostics (IVD) testing market. The company's objective is to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies. Its products include QL Care Analyzer, Immunoassay Tests, and Paramagnetic Beads. The business activity is primarily carried out through the region of Canada.

CardioGenics Holdings (CardioGenics Holdings) Headlines

No Headlines